By Fineline Cube 
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) announced on August 14, 2025, the establishment of its new Biopharmaceutical Business Unit (BBU). The unit will be led by Huo Shiwen, formerly the General Manager of the Comprehensive Business Unit and a Vice President at Hengrui.
Background of the BBU
In January 2024, Hengrui merged its former Comprehensive Product Business Unit and Imaging Business Unit to form a new Comprehensive Business Unit. This unit focuses on areas such as metabolism, autoimmune diseases, imaging, weight management, and respiratory conditions. Over the past year, the Comprehensive Business Unit has shown significant performance improvements. Its flagship product, Henagliflozin, has seen its market share continue to climb, surpassing Merck to rank second in the domestic SGLT2 product market. The unit has also had several Class 1 new drugs approved for market launch, indicating a positive development trend.
Biopharmaceutical Business Unit (BBU)
The newly established BBU will oversee more than 10 Class 1 innovative drugs that have already been marketed. These drugs cover areas such as metabolism, autoimmune diseases, pain relief, anesthesia, and critical care. In the recently announced initial screening list for national drug negotiations, several of its Class 1 innovative drugs passed the initial screening. These include key products such as its interleukin-17A inhibitor, JAK-1 inhibitor, and an ultra-long-acting PCSK9 inhibitor.-Fineline Info & Tech